Biotech company, Revvity (RVTY), has had a range of recent market activities and stock valuation changes. It revealed
Q3 earnings, with some metrics surpassing estimates; strong software growth was highlighted. However, the stock traded down on several occasions, leading to a valuation evaluation after share price rebounds. Revvity's valuation was seen as modest by Jim Cramer while various entities like
Russell Investments Group, Norges Bank, and JPMorgan Chase adjusted their shares. Likewise,
Hsbc Holdings and Prudential Financial increased their shares in Revvity whilst Rhumbline Advisers and Ceredex Value Advisors boosted stock positions. A new
In Vivo Imaging Innovation Center was launched, displaying a drive for innovation. Drama circled its
2025 profit forecast, initially increasing, then trimming it due to China's policy changes impacting diagnostics demand. Furthermore, Revvity is set to acquire ACD/Labs in Q4, further extending its software capabilities. The firm yet drew attention amidst lowered China Immunodiagnostics outlook resulting in a stock sink. Positive news showcased its
collaboration with Sanofi aimed at early detection of Type 1 Diabetes and a new program for the same cause.
Revvity RVTY News Analytics from Mon, 28 Apr 2025 07:00:00 GMT to Sat, 06 Dec 2025 06:11:12 GMT -
Rating 4
- Innovation 3
- Information 7
- Rumor 1
